Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Rhea-AI Summary
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) reported voting results from its Annual General Meeting held virtually on June 24, 2026. Shareholders approved all management resolutions, including the election of eight directors and the appointment of BDO Canada LLP as auditor for the next fiscal year.
Positive
- None.
Negative
- None.
News Market Reaction – CRDL
In the Jun 25 session, CRDL gained 0.97%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | AGM webcast | Neutral | -0.9% | Announcement of virtual webcast details for the June 24, 2026 AGM. |
| May 14 | Conference appearance | Neutral | +0.7% | Participation in H.C. Wainwright BioConnect investor conference with a webcasted fireside chat. |
| May 07 | Phase II publication | Positive | -1.5% | Phase II MAvERIC results accepted for publication supporting Phase III MAVERIC trial. |
| Apr 28 | Trial expansion | Positive | -2.1% | Expansion of U.S. MAVERIC Phase III trial network with enrollment reaching 75%. |
| Apr 14 | Clinical interview | Positive | +2.9% | Live interview highlighting MAVERIC Phase III, ARCHER results, and next-gen drug CRD-38. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed, generally modest single-day moves, with some selling pressure on otherwise positive clinical updates.
Key Terms
management information circular regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Resolutions proposed and approved at the AGM were:
- The election of the following directors for the ensuing year: Dr. Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Dr. Timothy Garnett, Jennifer Chao, Peter Pekos, and Colin Stott.
- The appointment of BDO Canada LLP as auditors of the Company for the next current fiscal year and the authorization of the Directors of the Company to fix the remuneration to be paid to the auditors.
The results of the voting on the election of Directors are as follows:
Nominees | Number of Shares For | Percentage of Votes Cast |
Dr. Guillermo Torre-Amione | 29,028,685 | 96.45 % |
David Elsley | 29,528,289 | 98.11 % |
Chris Waddick | 29,786,108 | 98.96 % |
Teri Loxam | 29,787,560 | 98.97 % |
Dr. Timothy Garnett | 29,855,359 | 99.19 % |
Jennifer Chao | 28,965,662 | 96.24 % |
Peter Pekos | 29,027,205 | 96.44 % |
Colin Stott | 29,785,651 | 98.96 % |
A webcast of the AGM will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.
The ARCHER Program also studied CardiolRx™ in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-reports-results-of-2026-annual-general-meeting-of-shareholders-302810079.html
SOURCE Cardiol Therapeutics Inc.